Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 29, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 165,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,379.15 pence per share.
- Treasury Holdings: 246,122,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,750,828,537 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 165,000 shares. Consequently, the total number of shares held in Treasury increased to 246,122,678. The filing does not provide comparative data against a prior period for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,750,828,537) for calculating ownership thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (246,122,678) for accurate voting rights calculations.
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.